Director Elizabeth Gulacsy filed a Form 4 with the SEC on November 3, 2026, disclosing the acquisition of 4,313 restricted stock units of TrueBlue, Inc. (NYSE:TBI) on November 2, 2026.

Key Highlights

  • Reporting person: Elizabeth Gulacsy, identified as a Director of TrueBlue, Inc.
  • Transaction date: November 2, 2026, with the form filed November 3, 2026.
  • Securities acquired: 4,313 restricted stock units (RSUs), recorded as acquired (transaction code A) at a price of $0.
  • Post-transaction ownership: 4,313 shares of Common Stock beneficially owned directly following the reported transaction.
  • Vesting schedule: According to the filing, the RSUs will vest in full one year from the grant date.
  • Settlement terms: The filing states the RSUs "will be settled for shares of Common Stock on a one-for-one basis in the future."

TrueBlue Director Gulacsy Receives RSU Grant Vesting in One Year

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Elizabeth Gulacsy, a director of TrueBlue, Inc. (NYSE:TBI), acquired 4,313 restricted stock units on November 2, 2026. The transaction was reported under transaction code A, designating the securities as acquired, and the price recorded was $0, consistent with a grant rather than an open-market purchase.

The filing's explanation of responses states that "the shares acquired represent a grant of restricted stock units that will be settled for shares of Common Stock on a one-for-one basis in the future," and that "the restricted stock units will vest in full one (1) year from the grant date." Following this transaction, Gulacsy holds 4,313 shares of Common Stock beneficially owned on a direct basis, as reported in Table I of the filing.

No derivative securities transactions were reported in Table II of the filing. The form was signed by Todd N. Gilman as attorney-in-fact on November 3, 2026, and was filed as an individual, single-reporting-person disclosure.

What Was Disclosed

TrueBlue director Elizabeth Gulacsy disclosed the receipt of 4,313 restricted stock units on November 2, 2026, at no cost, with full vesting set for one year from the grant date and settlement in Common Stock on a one-for-one basis.